New Asthma Drug heading for Human TrialsRPL554, a new drug for treating asthma, that faced trial at the Centre for Human Drug Research (CHDR) in the Netherlands on more than 60 people in 2008, is now expected to head for human trials during 2009.

The drug, which is hailed by some as nothing short of a miracle drug, may prove beneficial to 1.5 million people in the United States alone suffering from asthma and hay fever. This drug is expected to be available in the market in the coming three to four years pending to the success of initial trials for efficacy and safety.

Some researchers are of the view that this once-a-day asthma treatment option would act as a potential first-line therapy for curing patients suffering from asthma and hay fever. This will also mean that patients with asthma would now require only a single needle puff from their “lifesaving” inhalers to stop the symptoms.